Parathyroid gland volume and treatment resistance in patients with secondary hyperparathyroidism: a 4-year retrospective cohort study
Open Access
- 10 January 2025
- journal article
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (2) , sfae391
Abstract
Background: The role of parathyroid gland (PTG) ultrasonography in the management of secondary hyperparathyroidism after the introduction of calcimimetics remains unclear. Recent investigations have prompted renewed interest in the use of PTG ultrasonography for assessing treatment resistance to calcimimetics and determining the optimal timing for surgical intervention. This study aimed to explore the hypothesis that the PTG volume correlates with the calcimimetic dose. Methods: We retrospectively observed outpatients undergoing haemodialysis at baseline and a 4-year follow-up. PTG volume was measured using ultrasonography between January and December 2017 and January and December 2021. We examined the association between baseline PTG volume and calcimimetic doses after 4 years. Results: Of the 121 patients {median age 64 years [interquartile range (IQR) 54–72]}, 71 had PTG nodules on ultrasonography and the median total PTG volume was 34 mm3 (IQR 0–178). In the short dialysis vintage group, baseline parathyroid hormone levels tended to correlate with baseline calcimimetic doses; however, this trend was not observed in the extended dialysis vintage group. Baseline PTG volume correlated with the cinacalcet-equivalent calcimimetic dose (correlation coefficient 0.46; P < .001) after 4 years. The calcimimetic dose in the group with an estimated PTG volume >500 mm3 was ≈80 mg/day higher than that in the non-PTG nodule group after 4 years. In multivariate linear regression analysis, PTG volume >500 mm3 was associated with a high calcimimetic dose at 4 years in all analysis models. Conclusions: Assessing PTG volume using ultrasonography may help predict high calcimimetic doses.Keywords
Funding Information
- Japan Society for the Promotion of Science (20K17259, 23K07727)
This publication has 40 references indexed in Scilit:
- Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidismNephrology Dialysis Transplantation, 2008
- Activation of calcium-sensing receptor accelerates apoptosis in hyperplastic parathyroid cellsBiochemical and Biophysical Research Communications, 2007
- Persistent hyperparathyroidism in renal allograft recipients: Vitamin D receptor, calcium-sensing receptor, and apoptosisKidney International, 2006
- Role of pre-operative imaging using 99mTc-MIBI and neck ultrasound in patients with secondary hyperparathyroidism who are candidates for subtotal parathyroidectomyEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidismKidney International, 2005
- Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidismNephrology Dialysis Transplantation, 2003
- Presence of sonographically detectable parathyroid glands can predict resistance to oral pulsed-dose calcitriol treatment of secondary hyperparathyroidismAmerican Journal of Kidney Diseases, 2000
- The hyperparathyroidism of chronic renal failure: A disorder of growthKidney International, 1997
- Long-term effects of intravenous calcitriol therapy on the control of secondary hyperparathyroidismAmerican Journal of Kidney Diseases, 1996
- Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients.Journal of Clinical Investigation, 1993